Search
Search
Search
Close this search box.

Xybion announces that Novo Nordisk selects Pristima to manage pharmacology research studies across all research sites

Xybion Digital Inc. Press Releases

Morris Plains, N.J., October 1, 2015 /PRNewswire/ — Xybion Corporation announced today that Novo Nordisk (NYSE: NVO) has selected Xybion’s Pristima® Suite to manage all its non-GLP pharmacology studies in a global setting. The Pristima Suite is a preclinical software platform that offers a fully integrated, end-to-end enterprise solution for tracking and managing veterinary facilities and animal studies throughout the preclinical research process.

Xybion will provide a number of services and improvements to the Pristima platform to support non-GLP pharmacology studies, enabling Novo Nordisk to leverage the system for early drug discovery studies. In addition, Xybion will provide critical training and implementation services to configure Pristima and prepare the user community to meet Novo Nordisk best practices and reporting specifications.

Dr. Pradip Banerjee, CEO at Xybion stated, “Xybion is delighted to welcome Novo Nordisk to our client community; this opens yet another chapter in the Pristima history and is a further testament to the configurability that our engineers have built into the product. Our strategies facilitate scientists’ research activities, improve their efficiency and ensure the quality of their findings. I am excited that this project provides an for an additive set of functions targeted directly at the pharmacology teams of our pharmaceutical clients and further expands the integrative value that Xybion and Pristima bring to the market.”

Carlos Frade, VP of Preclinical R&D Solutions at Xybion commented, “After a diligent assessment in which Novo Nordisk and Xybion analyzed the approaches by which Pristima supports the operational planning, the data collection, the data evaluation, the instrument interfacing and efficiency improvements provided by Pristima, I am confident that we are delivering the best enterprise solution for drug discovery teams all over the world.”

About Xybion

Xybion is a leading SaaS company dedicated to providing life sciences and health systems companies with innovative software solutions to accelerate the transformation of today’s inventions into tomorrow’s approved medicines, devices, and diagnostic tests designed to save lives and keep employees safe. Our intelligent cloud platform and software solutions help companies accelerate digital transformation of processes, speed up innovation, optimize operations, reduce compliance risks, and achieve significant cost savings. Xybion is serving over 160 customers in 25 countries including all the top 20 global biopharmaceutical companies.

Xybion’s global scale and expertise brings employees around the world to help companies in life sciences, health systems, research institutions, and governments. We put over 40 years of expertise in action every day to help companies digitally transform their regulated business operations. Our unique solutions focus on employee health and safety, integrated preclinical lab management, early-stage drug discovery, digital lab solutions, regulatory compliance, GRC, quality management, predictive compliance, content management, and systems validation.

To learn more, please visit www.xybion.com.

About Pristima

The Pristima XD Suite is a fully integrated, end-to-end enterprise solution for tracking and managing veterinary facilities and research subjects throughout the preclinical research process. From ordering through the study submission process, the Pristima XD software platform delivers essential capabilities across the entire drug discovery process. The system enables organizations to maintain all preclinical data in one system, from compound receipt through dossier submission and slide archival. For over 40 years, global pharmaceutical companies and CROs have relied on Xybion to drive data management while ensuring quality, efficiency, and compliance.

Contacts

Media
Joseph Kalina
Xybion Corporation
609-512-5790 x 316
[email protected]

Share Press Release

LinkedIn
Facebook
Twitter
Pinterest
Reddit
WhatsApp
Email

Contact Investor Relations

Investor relations serves prospective investors like you seeking insight about Xybion Digital's operations, strategies, vision, and investment options.

Connect with our investor relations team today.